Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis.
Author: Zhang X1, Qing MJ1, Rao YH1, Guo YM2
Affiliation:
1Department of Neurosurgery, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.
2Department of Intensive Care Unit, The Third Affiliated of Guangzhou Medical University, Guangzhou, China. 812374982@qq.com.
Conference/Journal: Psychiatr Q.
Date published: 2020 Mar 7
Other:
Special Notes: doi: 10.1007/s11126-020-09726-5. [Epub ahead of print] , Word Count: 189
Vagus nerve stimulation (VNS) has been increasingly studied in treating treatment-resistant depression (TRD), but the findings have been mixed. This updated meta-analysis was conducted to examine the efficacy and safety of adjunctive VNS for TRD. Controlled studies reporting on the efficacy and safety of adjunctive VNS for TRD were screened, identified and analyzed. Standardized mean difference (SMD), risk ratio (RR) and their 95% confidence intervals (CIs) were analyzed using RevMan version 5.3. Three controlled studies with a total of 1048 patients with TRD compared VNS (n = 622) with control (n = 426) groups. Only one study was rated as 'high quality' using the Jadad scale. Adjunctive VNS was significantly superior to the control group regarding study-defined response [SMD:1.96 (95%CI:1.60, 2.40), P < 0.00001, I2 = 0%]. Patient-reported voice alteration occurred more frequently with adjunctive VNS for patients with TRD. No significant group differences were found regarding discontinuation due to any reason [RR:0.50 (95%CI:0.12, 2.09), P = 0.34, I2 = 85%]. Adjunctive VNS appeared to be effective and relatively safe treatment for TRD. Further randomized controlled trials are needed to confirm the efficacy and safety of VNS for TRD.
KEYWORDS: Depressive symptoms; Meta-analysis; Safety; Treatment-resistant depression; Vagus nerve stimulation
PMID: 32144640 DOI: 10.1007/s11126-020-09726-5
BACK
